Regulation of Single Strand Annealing Repair of Mammalian Chromosomal Breaks
Regulation of Single Strand Annealing Repair of Mammalian Chromosomal Breaks
批准号:
9901462
负责人:
Jeremy Michael Stark
金额:
$38.89万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-04-01 至 2022-03-31
关键词:
AffectAlu ElementsBRCA1 geneBiological AssayCell LineCellsChromosomal BreaksChromosomesDNADNA Double Strand BreakDNA SequenceDiseaseDouble EffectDouble Strand Break RepairElementsEventExcisionFailureFrequenciesG22P1 geneGeneticGenomeGoalsHuman GenomeIonizing radiationMaintenanceMediatingMediator of activation proteinMissionMusN-terminalNonhomologous DNA End JoiningPathway interactionsPatient-Focused OutcomesProteinsPublic HealthRadiation exposureRegulationRegulatory ElementRepetitive SequenceReporterResearchResistanceRoleSister ChromatidSystemTestingTherapeuticToxic effectTumor Suppressor ProteinsUnited States National Institutes of HealthVariantWorkbasecancer therapychromosome lossclastogenembryonic stem cellgenetic informationhomologous recombinationimprovedinhibitor/antagonistinnovationinsightmammalian genomemutantnovelnovel therapeutic interventionnucleasepublic health relevancerepairedresponsetumorubiquitin-protein ligase
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Ionizing radiation (IR) is a clastogenic agent, in that IR exposure causes DNA double-strand breaks (DSBs). Failure to restore the original DNA sequence following clastogen exposure causes genetic loss, which likely contributes to the cellular toxicity of these agents. Clastogen-induced loss of genetic information can be a consequence of DSB repair that is non-restorative, as occurs with Single Strand Annealing (SSA) repair. Namely, SSA is a type of homologous recombination (HR) pathway that uses flanking homologous repeat sequences to bridge the DSB, which causes a deletion rearrangement, with loss of the genetic information between the repeats. SSA has the potential to be catastrophic to the integrity of mammalian genomes, given the high level of repetitive elements, including the approximately one million Alu-type elements in the human genome. In contrast, another HR pathway, Homology-Directed Repair (HDR), is relatively restorative, since it uses the precise sister chromatid as a template. Our overall hypothesis is that SSA protects against chromosome loss, but regulation of this pathway to favor HDR vs. SSA, and limit the size of deletion rearrangements caused by SSA, are important for clastogen resistance. We have identified two factors as being important for the regulation of SSA: the tetratricopeptide repeat protein XAB2 is a mediator of SSA, whereas the E3 ubiquitin ligase RNF168 inhibits SSA in a manner that is magnified in cells depleted of the HR mediator BRCA1. To understand the regulation of SSA, our specific aims are: Aim 1. To define the SSA mediator function of XAB2. We will test the hypotheses that XAB2 promotes the end resection step of HR (HDR and SSA), and that motifs of XAB2 important for HR are critical for its interaction with another HR mediator,
PRP19. We will also test the hypothesis that hypomorphic XAB2 mutants deficient for SSA can retain function to mediate the restorative HDR pathway, and hence also be proficient at promoting clastogen resistance. Aim 2. To define the SSA inhibition function of RNF168. We will test the hypothesis that RNF168 functions in the same pathway as one SSA inhibitor (H2AX), but is distinct from another (Ku70, c-NHEJ pathway). Furthermore, we will test the hypothesis that the RNF168 C-terminus contains a negative regulatory domain that limits its anti-SSA activity. Aim 3. To examine how the distance between DSBs and repeat sequences affects the frequency and regulation of SSA. For this, we will develop a novel reporter for repeat-mediated deletion rearrangements, which will also include variations in repeat sequence divergence. This is relevant to understanding genetic loss, since the DSB/repeat distance defines the size of the deletion caused by SSA. This project is significant, as it will uncover mechanisms that influence genetic loss caused by clastogen exposure. The innovation in this work lies in the novel insight into XAB2 and RNF168 function during genome maintenance, and a unique reporter system to examine repeat-mediated deletion rearrangements.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Elucidating the role of DNAPKcs in chromosomal break end joining and clastogen resistance
-
批准号:10669605
-
项目类别:
-
资助金额:$39.45万
-
财政年份:2021
-
负责人:Jeremy Michael Stark
-
依托单位:
Elucidating the role of DNAPKcs in chromosomal break end joining and clastogen resistance
-
批准号:10415198
-
项目类别:
-
资助金额:$39.45万
-
财政年份:2021
-
负责人:Jeremy Michael Stark
-
依托单位:
Elucidating the role of DNAPKcs in chromosomal break end joining and clastogen resistance
-
批准号:10296356
-
项目类别:
-
资助金额:$40.26万
-
财政年份:2021
-
负责人:Jeremy Michael Stark
-
依托单位:
The role of O-GlcNAcylation in DNA damage repair and cancer therapy
-
批准号:10650718
-
项目类别:
-
资助金额:$38.78万
-
财政年份:2019
-
负责人:Jeremy Michael Stark
-
依托单位:
The role of O-GlcNAcylation in DNA damage repair and cancer therapy
-
批准号:10171810
-
项目类别:
-
资助金额:$39.57万
-
财政年份:2019
-
负责人:Jeremy Michael Stark
-
依托单位:
The role of O-GlcNAcylation in DNA damage repair and cancer therapy
-
批准号:10399545
-
项目类别:
-
资助金额:$38.78万
-
财政年份:2019
-
负责人:Jeremy Michael Stark
-
依托单位:
Regulation of Single Strand Annealing Repair of Mammalian Chromosomal Breaks
-
批准号:9236171
-
项目类别:
-
资助金额:$38.89万
-
财政年份:2016
-
负责人:Jeremy Michael Stark
-
依托单位:
THE MECHANISM OF RECOMBINATION-MEDIATED LOSS OF HETEROZYGOSITY IN HUMAN
-
批准号:7382140
-
项目类别:
-
资助金额:$21.12万
-
财政年份:2006
-
负责人:Jeremy Michael Stark
-
依托单位:
Mechanistic steps of homologous repair in mammalian cells
-
批准号:7658248
-
项目类别:
-
资助金额:$21.83万
-
财政年份:2006
-
负责人:Jeremy Michael Stark
-
依托单位:
Mechanistic steps of homologous repair in mammalian cells
-
批准号:7895013
-
项目类别:
-
资助金额:$21.83万
-
财政年份:2006
-
负责人:Jeremy Michael Stark
-
依托单位:
Correct end use during end joining and radioresistance
-
批准号:8676686
-
项目类别:
-
资助金额:$21.05万
-
财政年份:2006
-
负责人:Jeremy Michael Stark
-
依托单位:
Correct end use during end joining and radioresistance
-
批准号:8370791
-
项目类别:
-
资助金额:$21.7万
-
财政年份:2006
-
负责人:Jeremy Michael Stark
-
依托单位:
Mechanistic steps of homologous repair in mammalian cells
-
批准号:7279126
-
项目类别:
-
资助金额:$21.83万
-
财政年份:2006
-
负责人:Jeremy Michael Stark
-
依托单位:
Mechanistic steps of homologous repair in mammalian cells
-
批准号:7085607
-
项目类别:
-
资助金额:$22.48万
-
财政年份:2006
-
负责人:Jeremy Michael Stark
-
依托单位:
Correct end use during end joining and radioresistance
-
批准号:8765425
-
项目类别:
-
资助金额:$7.33万
-
财政年份:2006
-
负责人:Jeremy Michael Stark
-
依托单位:
Mechanistic steps of homologous repair in mammalian cells
-
批准号:7478540
-
项目类别:
-
资助金额:$21.83万
-
财政年份:2006
-
负责人:Jeremy Michael Stark
-
依托单位:
Correct end use during end joining and radioresistance
-
批准号:9066590
-
项目类别:
-
资助金额:$21.7万
-
财政年份:2006
-
负责人:Jeremy Michael Stark
-
依托单位:
Correct end use during end joining and radioresistance
-
批准号:8507612
-
项目类别:
-
资助金额:$20.39万
-
财政年份:2006
-
负责人:Jeremy Michael Stark
-
依托单位:
Analytical Cytometry Core
-
批准号:10328520
-
项目类别:
-
资助金额:$8.85万
-
财政年份:1997
-
负责人:Jeremy Michael Stark
-
依托单位:
Analytical Cytometry
-
批准号:10628585
-
项目类别:
-
资助金额:$5.62万
-
财政年份:1997
-
负责人:Jeremy Michael Stark
-
依托单位:
海外基金